<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Acquired or hereditary prothrombotic risk factors may lead to cerebral venous sinus <z:mp ids='MP_0005048'>thrombosis</z:mp> (CVST), particularly when other predisposing factors coexist </plain></SENT>
<SENT sid="1" pm="."><plain>A 57-year-old man experienced right leg <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo>, severe <z:mp ids='MP_0005048'>thrombosis</z:mp> of the <z:e sem="disease" ids="C0019112" disease_type="Disease or Syndrome" abbrv="">haemorrhoid</z:e> plexus and CVST over a 12-month period during which he was taking sildenafil regularly twice a week </plain></SENT>
<SENT sid="2" pm="."><plain>Sildenafil is a phosphodiesterase 5 (PDE5)-inhibitor used for <z:hpo ids='HP_0000802'>erectile dysfunction</z:hpo> (ED) </plain></SENT>
<SENT sid="3" pm="."><plain>A slight reduction in antithrombin III and free protein S levels was demonstrated </plain></SENT>
<SENT sid="4" pm="."><plain>After suspension of sildenafil and six months on oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi>, clinical improvement was obtained </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0004850'>Recurrent venous thrombosis</z:hpo>, including CVST, may complicate prolonged treatment with PDE5-inhibitors in subjects at risk </plain></SENT>
<SENT sid="6" pm="."><plain>Periodic monitoring of clotting factors is recommended in these subjects </plain></SENT>
</text></document>